Need help finding what you are looking for?
Contact Us
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1739813
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1739813
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Type, By Drug Type, By Distribution Channel, By Geography
PUBLISHED:
PAGES: 160 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Transthyretin Amyloid Cardiomyopathy Treatment Market is estimated to be valued at USD 2.91 Bn in 2025 and is expected to reach USD 19.37 Bn by 2032, growing at a compound annual growth rate (CAGR) of 31.1% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 2.91 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 31.10% | 2032 Value Projection: | USD 19.37 Bn |
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a common type of amyloidosis, which affects the heart, causing heart muscles to stiffen and eventually lead to heart failure. ATTR-CM often causes symptoms of heart failure, such as fatigue, shortness of breath and peripheral edema, and other symptoms related to buildup of amyloid fibrils in the body. There are two forms of transthyretin amyloid cardiomyopathy (ATTR-CM); hereditary transthyretin amyloidosis (hATTR) and wild type transthyretin amyloidosis (wtATTR). This disease is often diagnosed only after symptoms have become severe.
Market Dynamics
Rising incidence of transthyretin amyloid cardiomyopathy is expected to drive the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market growth. For instance, according to the National Center for Biotechnology Information (NCBI), an article published in December 2019, reports the study of the Japan Medical Data Vision (MDV), which was a hospital based database from January 2010 to September 2018 to estimate the number of currently diagnosed ATTR-CM patients. This study reports data of over 9 years of study which included 3255 patients (155.8 per million adult patients in the MDV database) to 3992 patients (191.1 per million) diagnoses of wild type transthyretin amyloidosis (wtATTR).
However, lack of awareness about transthyretin amyloid cardiomyopathy (ATTR-CM) is expected to hinder the market growth. For instance, according to an article published by Amyloidosis. Amyloidosis Foundation in 2016, awareness of transthyretin amyloid cardiomyopathy (ATTR-CM) is low among the general public as well as healthcare professionals and therefore, this condition often is unnoticed.
Key features of the study:
- This report provides in-depth analysis of the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study are Pfizer Inc., GlaxoSmithKline Plc., Eidos Therapeutics, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Prothena Corporation plc, Intellia Therapeutics, Inc., Corino Therapeutics, Inc. among others
- Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
- The global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market.
Detailed Segmentation:
- Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Type:
- Hereditary Transthyretin Amyloidosis (hATTR)
- Wild Type Transthyretin Amyloidosis (wtATTR)
- Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Drug Type:
- Transthyretin Stabilizers
- Nonsteroidal anti-inflammatory drugs (NSAID)
- RNAi therapy
- Others
- Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Company Profiles
- Pfizer Inc.
- GlaxoSmithKline Plc.
- Eidos Therapeutics
- Ionis Pharmaceuticals, Inc.
- Alnylam Pharmaceuticals
- Prothena Corporation plc
- Intellia Therapeutics, Inc.
- Corino Therapeutics, Inc.
Product Code: CMI4321
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Type
- Market Snippet, By Drug Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Approvals/Launches
- Mergers, Acquisitions, and Collaborations
- Regulatory Scenario
- Recent Trends
- Pricing Analysis
- Key Developments
- PEST Analysis
- Porter's Analysis
4. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market - COVID-19 Impact Analysis
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
5. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Type, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
- Hereditary Transthyretin Amyloidosis (hATTR)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Segment Trends
- Wild Type Transthyretin Amyloidosis (wtATTR)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Segment Trends
6. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Drug Type, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
- Transthyretin Stabilizers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Segment Trends
- Nonsteroidal Anti-inflammatory Drugs (NSAID)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Segment Trends
- RNAi Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Segment Trends
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Segment Trends
7. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Distribution Channel, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Segment Trends
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Segment Trends
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Segment Trends
8. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Region, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032, (US$ Bn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profiles
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- GlaxoSmithKline Plc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Eidos Therapeutics
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Ionis Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Alnylam Pharmaceuticals
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Prothena Corporation plc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Intellia Therapeutics, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Corino Therapeutics, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Analysts' Views
- Pfizer Inc.
10. Section
- References
- Research Methodology
- About us and Sales Contact
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.